Clinical study of syndrome differentiation standards for chronic skin ulcer of lower limbs

2009 ◽  
pp. 1139-1144 ◽  
Author(s):  
YJ Wang
2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Rolando Tasinato ◽  
Paolo Zangrande

Un’ulcera cutanea cronica degli arti inferiori rappresenta l’epifenomeno di varie situazioni patologiche che possono coinvolgere, a vari livelli e con diversi gradi di interessamento, i sistemi venoso, arterioso e linfatico della gamba. Recentemente sono state pubblicate numerose evidenze secondo cui i glicosaminoglicani (GAG) svolgono un ruolo importante nella riepitelizzazione delle ulcere cutanee croniche degli arti inferiori, in particolare per quanto riguarda le ulcere ad eziopatogenesi vascolare venosa o mista. In questo articolo riportiamo la nostra esperienza nel trattamento delle ulcere cutanee croniche degli arti inferiori con una metodica che prevede il debridement secondo il protocollo TIME, antisepsi con una soluzione di iodopovidone al 10% la successiva l’applicazione di una medicazione bioattiva contenente GAG e acido ialuronico. Questa metodica è stata confrontata con un’analoga metodica che prevede sempre lo stesso tipo di debridement e di antisepsi con soluzione di iodopovidone al 10% affiancata a una medicazione non bioattiva. A chronic skin ulcer in the lower limbs represents the epiphenomenon of pathologies that may involve, at various levels, the venous, arterial, lymphatic and nervous systems of the leg, which must be identified and adequately treated. Recently, there has been increasing evidence that glycosaminoglycans (GAGs) play a role in the re-epithelialization of chronic skin ulcerative wounds of the lower limbs, particularly as regards ulcers of venous and arterial vascular origin. In this paper we report our experience in the treatment of chronic skin ulcers with debridement according to the TIME Wound Bed Preparation protocol with application of a bioactive dressing containing GAGs and hyaluronic acid, compared to a technique using a standard dressing involving the cleansing of the wound with 10% povidone iodine solution.


2019 ◽  
Vol 18 (1) ◽  
pp. 97-103
Author(s):  
Jiaojiao Zhong ◽  
Yu Lan ◽  
Shuying Fu ◽  
Jing Zhang ◽  
Sha Lu ◽  
...  

Chronic skin ulcer (CSU) often combines with a variety of refractory factors that respond poorly to routine treatments. Botulinum toxin A (BTX-A) can be injected subcutaneously to improve the local blood supply, to reduce pain, and to promote wound healing. At present, few reports have mentioned BTX-A injection for chronic skin ulcer treatment. We observed the effect of four cases that used BTX-A to treat CSU and provided a brief review of the literature. Four cases of CSUs with 4 different causes were treated with BTX-A injection (4 U/cm2). The specific operation is as follows: local, multipoint, cyclic, equidistant, and subcutaneous injections with a depth of 6 to 8 mm. The ulcer area was significantly reduced. Subsequently, the ulcer healed within 20 to 48 days. Botulinum toxin A is recommended as an important treatment for chronic skin ulcer that can improve healing of skin ulcers with various etiologies.


1996 ◽  
Vol 19 (6) ◽  
pp. 429-434 ◽  
Author(s):  
S Bertone ◽  
C Gili ◽  
A Moizo ◽  
L Calegari

2016 ◽  
Vol 14 (10) ◽  
pp. 1032-1033 ◽  
Author(s):  
Jörg Tittelbach ◽  
Susanne Metz ◽  
Peter Elsner
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document